Trial Profile

An Open Label Randomized Clinical Trial, to Evaluate the Treatment With Darunavir/Ritonavir + Lamivudine Once Daily Versus Continuing With Darunavir/Ritonavir Once Daily + Tenofovir/Emtricitabine or Abacavir/Lamivudine in HIV Infected Subject With Suppressed Plasma Viremia

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 06 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Darunavir (Primary) ; Lamivudine (Primary) ; Ritonavir (Primary) ; Abacavir; Emtricitabine/tenofovir disoproxil fumarate
Indications HIV infections
Focus Therapeutic Use
Acronyms DUAL

11 May 2016 Status changed from active, no longer recruiting to completed.
22 Jan 2016 Planned End Date changed from 1 Dec 2015 to 1 Apr 2016. as reported by ClinicalTrials.gov.
22 Jan 2016 Planned primary completion date changed from 1 Dec 2015 to 1 Apr 2016 as reported by ClinicalTrials.gov.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com